CardioVIP

About CardioVIP

CardioVIP, founded in 2011 and headquartered in Sugar Land, TX, operated as a provider of healthcare programs focused on cardiovascular disease prevention and management. The company ceased operations around November 2016.

The management team included CEO Frank Ruderman, who previously led Berkeley HeartLab to a $195 million acquisition by Celera, and President Jamie Richter, a co-founder with experience at companies like Johnson & Johnson and CardioNet. The team aimed to leverage its experience from Berkeley HeartLab to build CardioVIP. The company was venture-backed, having raised approximately $7.46 million through Series A and Series B funding rounds.

CardioVIP's business model centered on providing physicians with advanced diagnostic tools to better assess a patient's risk for heart disease and stroke. The company developed algorithms that integrated data from blood biosensors and physical diagnostic tests. This information was processed in partnership with Cleveland HeartLab to generate tailored treatment plans. The service was delivered to physicians and patients through a proprietary, web-based medical communication system.

The core offering was the CardioVIP test, a comprehensive panel that analyzed five key components contributing to cardiovascular disease: vascular inflammation, dyslipidemia, pre-diabetes, hypertension, and metabolic disease. It included advanced bio-monitors like Myeloperoxidase (MPO) and Lp-PLA2 to predict short-term risk of cardiovascular events, alongside genetic tests and micronutrient analysis. A unique feature was the use of web-based health coaches, called "iCoaches," who worked with patients to ensure adherence to their personalized treatment plans and provide ongoing support. The target clients were individuals with known cardiovascular disease, diabetes, or other risk factors such as hypertension and obesity.